Delhi ILBS JRF Job – MSc Biotech, Immunology & Life Sciences Walk-In
INSTITUTE OF LIVER & BILIARY SCIENCES
(An Autonomous society under the Govt. of NCT of Delhi)
Sector D-1, Vasant Kunj, New Delhi, India
Walk-in -Interview for the post of Junior Research Fellow under DBT project
Walk-in -Interview for the post of Junior Research Fellow on contractual basis for the project entitled “Designing Bispecific CAR-NK cell targeting Alpha-fetoprotein (AFP) and glypican-3(GPC-3) present in Hepatocellular carcinoma(HCC)” funded by DBT on 23-January 2024 at the Institute of Liver & Biliary Sciences, D-1, Vasant Kunj, Delhi-110070.
Post: Junior Research Fellow (JRF)
No. of Post: 1
Consolidated Remuneration: Rs. 31,000 per month + 24% HRA
Eligibility Criteria: M.Sc. in Life Sciences/Biotechnology/Biomedical/Immunology
Age Limit: Maximum 28 years (relaxation as per government rules)
Desirable Experience: Experience in immunology
Interview Details:
- Date: 23rd January 2024
- Time: Walk-in interview
- Location: Institute of Liver & Biliary Sciences, D-1, Vasant Kunj, Delhi-110070
General Instructions:
- Project Title: “Designing Bispecific CAR-NK cell targeting Alpha-fetoprotein (AFP) and glypican-3(GPC-3) present in Hepatocellular carcinoma (HCC)”
- Principal Investigator: Dr. Nirupma Trehanpati, Professor (MCM), Institute of Liver and Biliary Sciences, D-1, Vasant Kunj, New Delhi-110070
- Funding Agency: Department of Biotechnology (DBT)
- Candidates are required to bring photocopies and originals of degree/certificate/ diploma/testimonials along with an updated resume.
- No TA/DA will be provided for attending the interview.
Keywords: Govt NCT Delhi ILBS, Junior Research Fellow, MSc Biotech, Immunology, Life Sciences, Walk-in Interview, DBT project, Institute of Liver & Biliary Sciences. Delhi ILBS JRF Job – MSc Biotech, Immunology & Life Sciences Walk-In. Please ensure you are subscribed to the Biotecnika Times Newsletter and our YouTube channel to be notified of the latest industry news. Follow us on social media like Twitter, Telegram, Facebook
